Robustness potency

The third step is to optimize the lead molecule through iterative chemical synthesis and biological testing, aiming to obtain molecules with the required potency (typically nanomolar), selectivity, bioavailability, and DMPK (drug metabolism and pharmacokinetics) properties. This step usually requires considerable time and resources usually the synthesis of hundreds of compounds is needed to deduce a robust SAR (structure-activity relationship). Such resources can be considerably reduced and the... 

Benzamides constitute a fourth dass of HDAC inhibitors. One example, MS-275, is a phenylenediamine derivative that exhibits robust HDAC inhibition in patients with advanced myeloid leukemia as well as refractory solid tumors or lymphoma in Phase I studies [72]. MS-275 is currently in Phase II trials. In a recent study aimed at optimizing the benzamide scaffold, several bis-(aryl) type analogs were synthesized and evaluated for their activity against a panel of HDACs [85]. Moradei et al. found that a thienyl substitution para to the free amino group in the phenylenediamine core rendered inhibitors specific for HDACsl, 2 with potency superior to that of MS-275. Isoform-specific inhibitors should aid in dissecting the roles of HDACs in normal cellular fundioning and cancer. 

An alternative way to validate the critical function eliciting the disease-relevant phenotype is the use of tool modulators these can be small molecules, peptides, or antibodies that may not have the properties to be considered a drug, but may display sufficient potency and selectivity to be used to interrogate the specific protein function in the relevant system. Such tools, however, are rarely available with the required characteristics to allow for a robust interpretation of the experiment. The exception is represented by the... 

Related to CYP activity, PXR interestingly displayed a negative correlation/association with reprodnctive toxicity. In general, PXR lowered the false positive rate of the model by lowering the model score of chemicals with nonspecific and low potency nuclear receptor activity. Robust PXR activity is an indication of potent xenos-ensing and potentially rapid metabolism. 

Rarely did the intramuscular or intravenous doses exceed 1.5 times the Incapacitating dose. Inhalation doses were higher, but potencies were lower by this route (usually about 60 percent of that by the Intravenous or intramuscular route). Compared with doses described in the scientific literature on atropine coma therapy 18-23 or scopolamine therapy, the BZ doses to which volunteers were exposed appear modest. As much as 20 times the ID50 of atropine and 30-40 times the ID50 of scopolamine have been administered in the past by clinicians—often to older and less robust patients. Many patients received multiple exposures of this magnitude over a period of days or weeks. These therapeutic procedures, reported several decades ago in refereed journals, actually stressed and advocated the benefits of such treatment, despite occasional deaths (most of which appear to have been caused by hyperthermia). 

An example of the minimum requirement for potency assay of the drug substance and drug product is tabulated in Table 4. Note that the postponement of intermediate precision is aligned with previous discussion that the use of early phase analytical method resides mainly in one laboratory and is used only by a very limited number of analysts. Each individual company s phased method validation procedures and processes will vary, but the overall philosophy is the same. The extent of and expectations from early phase method validation are lower than the requirements in the later stages of development. The validation exercise becomes larger and more detailed and collects a larger body of data to ensure that the method is robust and appropriate for use at the commercial site. 

The validation requirements are similar to those applied when validating a potency method. Although not listed in Table 4.1, robustness of the various method parameters should be assessed (e.g., the stability of sample solutions). Details of the principles behind these requirements are presented in Section 2.4. 

Robustness for HPLC Analysis. The investigation of the effect of column, mobile phase, HPLC solution stability, and wavelength is performed in a manner similar to the HPLC potency/related substance assay. For solution stability, the... 

In order to develop a robust formula for a drug product (pharmaceutical dosage form) it is important to understand the chemical and physical properties of the API in conjunction with excipients that may be used to create the most stable product formula in terms of activity and potency. An outline of possible preformulation studies that should be conducted to ensure a proper and complete understanding of the chemical and physical properties of the API is presented in Table 3. 

By far the most comprehensive research into AHR-related effects of PCDD/Fs on fish was a retrospective analysis of Lake Ontario lake trout reproductive impairment due to AHR-mediated early life stage mortality [16]. This includes blue sac disease as well as sublethal effects, which may increase susceptibility of sac fry and alevins to increased mortality and predation during swim-up. Lake trout are more susceptible to AHR-mediated toxic effects than any other Great Lakes species, with the possible exception of mink. WHO TEFs for fish were used to calculate the 2378-TCDD equivalent (TECegg or TEQ) concentrations in lake trout eggs. The validity of the additive toxicity equivalence model was established through early life stage trout toxicity tests. The WHO fish TEFs are likely to be fairly robust for lake trout, since they were determined primarily from relative potency values for effects in embryos of a related salmonid, rainbow trout, even if the relative sensitivity of the species to 2378-TeCDD toxicity may be different. 

Pharmacotoxic and pharmacokinetic studies carried out for the new antitumor drug Aviscumine (rViscumin) were supported by a robust quantitative IPCR assay developed by Adler et al. [66, 85], The potency of this protein-based drug, derived from recombinant mistletoe lectine, required initial doses well below the quantification range accessible by conventional ELISA. An IPCR assay was adapted and validated for the quantification of rViscumin in standardized human serum [66, 85, 86] and subsequently... 

---